This study evaluated the efficacy and safety of docetaxel, cisplatin and 5fluorouracil/leucovorin as neoadjuvant chemotherapy before surgery (NCT group; n = 29) compared with postoperative chemotherapy alone (non-NCT group; n = 26) in the treatment of Borrmann type IV gastric carcinoma. Primary tumour response rate, surgical parameters, incisededge residue rate, lymphatic metastasis status and side-effects were evaluated. The overall response rate was 58.6% in the NCT group, which included three (10.3%) patients in complete remission and 14 (48.3%) patients in partial remission. The postoperative pathological complete response rate was 6.9% (two patients) in the NCT group. NCT was associated with a significant increase in the radical resection rate and a significant decrease in the rate of incised-edge residues, compared with postoperative chemotherapy alone. Sideeffects due to NCT were minimal and resolved with appropriate treatment. There were no chemotherapy-related deaths in either group. In conclusion, docetaxel, cisplatin and 5-fluorouracil/leucovorin was an effective and well-tolerated NCT regimen for Borrmann type IV gastric cancer.
Introduction
The classification system for advanced gastric carcinomas was developed by Borrmann in 1926, and has been widely used to describe the endoscopic and gross findings of these conditions. 1 Borrmann type IV gastric carcinomas, including linitis plastica, are characterized by poorly differentiated tumour cells with diffusely infiltrative involvement of the stomach. 2 -5 Approximately 10% of gastric cancers are Borrmann type IV, which is a relatively undifferentiated carcinoma with little or no gland-forming capability. 5 -9 Although there have been advances in the diagnosis and medical treatment of gastric cancer, most X-C Sun, J Lin, A-H Ju Borrmann type IV gastric cancer treatment with NCT Borrmann type IV tumours are not detected at an early stage and the prognosis remains poor. 10, 11 The 5-year survival rate after gastric resection ranges from 0 to 17% for Borrmann type IV tumours compared with 35 -70% for other types of gastric carcinoma. 12 -16 In recent years, neoadjuvant chemotherapy (NCT) in the form of preoperative chemotherapy has been proposed as a method to improve the efficacy of subsequent surgery. 17 -20 To evaluate whether NCT provides treatment benefits in patients with Borrmann type IV gastric cancer, a combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin was used as NCT in the present study, and the efficacy of this treatment regimen was compared with the same combination using a postoperative chemotherapy regimen only (non-NCT).
Patients and methods

PATIENTS
This study included patients with Borrmann type IV gastric cancer recruited from Yantai Yuhuangding Hospital, Yantai, China, between July 2008 and July 2010. The patients were randomly divided into two groups according to a computer-generated randomization schedule: the NCT group received NCT prior to surgery; the non-NCT group did not receive preoperative NCT. Each patient was examined at baseline using routine gastroscopy and pathology, and underwent an upper alimentary tract barium meal examination. An abdominal computed tomography (CT) scan was used for diagnosis, to measure the size and dimensions of the tumour, and to judge the extent of invasion of the surrounding tissues. Patients with metastases outside of the abdominal cavity were excluded from the study. Each patient's Karnofsky performance scale score was > 80%.
The study protocol was approved by the Ethics Committee of Yantai Yuhuangding Hospital. Written informed consent was obtained from each participant before study entry.
TREATMENT REGIMEN
All patients were treated at Yantai Yuhuangding Hospital. The NCT group received three cycles of preoperative chemotherapy each separated by an interval of 21 days as follows. Docetaxel 75 mg/m 2 was administered by intravenous (i.v.) infusion, with dexamethasone 7.5 mg given orally 12 h before and after using docetaxel. Dexamethasone 10 mg i.v. injection, cimetidine 0.4 g i.v. infusion and phenergan 25 mg intramuscular injection were administered before the chemotherapy. The NCT group also received 5-fluorouracil 500 mg/m 2 by i.v. infusion on days 1 -3, and leucovorin 200 mg/m 2 in 250 ml physiological saline by i.v. injection for 30 min before 5-fluorouracil, then by continuous i.v. infusion over 2 h on days 1 -5. Heart rate, respiration, blood pressure and pulse rate were monitored at the beginning of the i.v. infusions. Treatment effects and side-effects were evaluated, using patientreported questionnaires and CT scans, after completion of the three cycles of preoperative chemotherapy and again at 6month intervals thereafter. Surgery was carried out days 7 -10 after completion of the three cycles of NCT, i.e. 3 months after completion of diagnostic tests.
The non-NCT group received routine surgery after being hospitalized, i.e. 3 days after completion of diagnostic tests.
Both groups received postoperative chemotherapy, starting 1 month after surgery, using the regimen described above; the NCT group received three cycles and the X-C Sun, J Lin, A-H Ju Borrmann type IV gastric cancer treatment with NCT non-NCT group received six cycles of postoperative chemotherapy.
EVALUATION OF RESPONSE AND TOXICITY
Following NCT treatment a gastroscopy, an upper alimentary tract barium meal examination and an abdominal CT scan were performed to evaluate tumour size, peristalsis of the stomach wall and local metastasis. Response to treatment was assessed by CT scanning according to the Response Evaluation Criteria in Solid Tumours. 21 Response of the primary tumour after completion of treatment was evaluated in both groups according to the World Health Organization (WHO) criteria for complete remission and partial remission. 22 The rates of disease stabilization and progression were assessed according to WHO criteria, 22 pathological response and changes in tumour characteristics in the NCT group only. Surgical resection rates, surgical parameters, incised-edge residue rates and the pathological conditions of the two groups were compared after completion of treatment in both groups. Chemotherapy toxicity was classified according to WHO criteria. 22
FOLLOW-UP STUDIES
All patients were followed up once every 3 months during the first postoperative year and then once every 6 months during subsequent years. Survival rates were calculated.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® software package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . A two-sided χ 2 -test was used to compare differences between the two treatment groups. The Kaplan-Meier test was used to compare survival periods. A value of P < 0.05 was considered to be statistically significant.
Results
In total, 55 patients with Borrmann type IV gastric cancer were enrolled in the study and randomly allocated into one of the two groups: the NCT group included 29 patients; the non-NCT group included 26 patients. There were 37 males and 18 females, aged between 33 and 72 years (mean age 52.6 years).
Radical total gastrectomy was performed in 15/29 (51.7%) patients in the NCT group and in 8/26 (30.8%) patients in the non-NCT group (P < 0.05). Nine patients in the NCT group and 12 in the non-NCT group had palliative excisions, while five patients in the NCT group and six in the non-NCT group had palliative surgery (such as gastrojejunostomy, jejunostomy or exploratory laparotomy). The surgical resection rate was 82.8% (24/29 patients) in the NCT group and 76.9% (20/26 patients) in the non-NCT group; this difference was not significantly different. The incised-edge residue rate was 8.3% (2/24 patients) in the NCT group and 25.0% (5/20 patients) in the non-NCT group (P < 0.05).
Of the six patients in the NCT group who had progressive disease, a barium meal examination of the upper alimentary tract and an abdominal CT scan showed that the tumour size, and the size of tumescent lymph nodes of the stomach, had reduced after preoperative NCT compared with before NCT (Table 1 ). In addition, the compliance of the stomach had improved, gastric peristalsis had increased and the edge of the tumour and other tissues had cleared following treatment.
Postoperative pathological examinations showed that the complete pathological response rate was 6.9% (2/29 patients) in the X-C Sun, J Lin, A-H Ju Borrmann type IV gastric cancer treatment with NCT NCT group. Of the 15 patients in the NCT group who underwent radical resection, there were four with no lymph node metastases, three with pN1 (1 -6 lymph node metastases), five with pN2 (7 -15 lymph node metastases) and three with pN3 (> 15 lymph node metastases). Lymph node metastases were observed in all eight patients in the non-NCT group who underwent radical resection: two with pN1, two with pN2, and four with pN3. The pN0 + pN1 rate for the NCT group (46.7%; 7/15 patients) was significantly higher than that for the non-NCT group (25.0%; 2/8 patients) (P < 0.05).
In the NCT group, 10 No statistically significant differences for before versus after preoperative chemotherapy (P > 0.05); two-sided χ 2 -test. The main side-effects in the NCT group were low leucocyte counts, gastrointestinal symptoms and hair loss. Leucocyte counts quickly increased to normal levels when recombinant human granulocyte colonystimulating factor was given by i.v. injection. Gastrointestinal symptoms were treated with granisetron (i.v. injection). Liver and kidney damage was minimal. There no were toxicityrelated deaths observed in either group.
Discussion
Despite progress in the treatment of gastric cancer in recent years, the management of Borrmann type IV gastric cancer remains unsatisfactory. The prognosis for patients with Borrmann type IV gastric cancer is poor and the 5-year survival rate is 0 -5%. 23 Borrmann type IV gastric cancers have a characteristic biological behaviour, and usually present as highly malignant tumours based on their histopathological grade, such as poorly differentiated adenocarcinomas and undifferentiated carcinomas. 23 The extent of tissue invasion is usually large and most Borrmann type IV gastric cancers will invade adjacent organs. 23 Lymph node metastasis and metastasis beyond the lymph nodes usually occur early in the disease course. 23 It is difficult to prolong the survival of Borrmann type IV gastric cancer patients even after radical resection. 24 Neoadjuvant chemotherapy is defined as the use of systemic or local chemotherapy before other therapies such as ablation therapy, surgery or radiotherapy. NCT can reduce the tumour burden, reduce the tumour size, lower the primary tumour stage and increase the success rate of radical resections for gastric cancer. 25 It helps to kill subclinical disseminated tumours and improves the prognosis of gastric cancer. 26 NCT can also improve the success rate of secondary operations for non-resectable advanced gastric carcinoma and is not usually associated with fatal complications. 27 Docetaxel, a taxane, is a widely used chemotherapy drug: efficacy rates for docetaxel monotherapy have been reported as 15 -24%; and when it is given in combination with 5-fluorouracil and cisplatin therapy, efficacy rates have been reported to be 22 -65% in advanced gastric carcinoma. 28, 29 When patients with advanced Borrmann type IV gastric cancer were treated with a combination therapy consisting of docetaxel, cisplatin and i.v. injections of 5-fluorouracil and tetrahydrofolic acid, complete remission was achieved by 11% and partial remission was achieved by 40% of patients, while stabilization of disease was achieved by 20% of patients. 30 One group of patients with Borrmann type IV gastric cancer in the present study received docetaxel, cisplatin and 5-fluorouracil/leucovorin as NCT; a second group received this regimen postoperatively. The overall clinical response rate in patients receiving NCT was 58.6% and the percentage who had a complete pathological response was 6.9%. The use of NCT improved the success rate of surgery and increased the survival time by reducing tumour size and lymph node size, keeping patients at a lower clinical stage, increasing the radical resection rate, and decreasing the incised-edge residue rate.
The present study showed that docetaxel, cisplatin and 5-fluorouracil/leucovorin, used as NCT, was effective and well tolerated in patients with Borrmann type IV gastric cancer. There were no deaths, and the main
